Hello, this is Dr Steve Tyring in Houston, Texas.

I started prescribing KLISYRI^® when it became available after having done the clinical trials that were published in the New England Journal of Medicine last year. And in those trials, we saw a good rate of clearance of the actinic keratoses, good compliance by the patients, and based upon observations in the trials, we started prescribing it as soon as it became commercially available.

Patients that benefit most from KLISYRI^® are those that have more than just a couple of AKs. So, when they apply the five-day course of KLISYRI^®, usually by the fifth day they will have some erythema. But if they have any pruritus or discomfort, it's usually quite mild and well tolerated. So, by the fifth day, they've completed the course and are usually very compliant. And when they come back, the majority of their AKs have cleared and patients generally are quite satisfied with the results.

When any fellow dermatologists who haven’t prescribed KLISYRI^® ask me about my advice for treating AKs, my recommendations are to use field therapy for those patients that have more than just a couple of AKs and with KLISYRI^®, after five days, the patients will have usually demonstrated good compliance and they will usually see a high rate of clearance. So, good compliance, good results, the short term and good results in the long term, are all the reasons that I recommend KLISYRI^® to my patients for field therapy of their AKs.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Please see full Prescribing Information.

References: 1. Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384:512-520. 2. KLISYRI^®. Prescribing information. Almirall, LLC.

KLISYRI^® is a registered trademark of Almirall, LLC.
© 2005-2023
All rights reserved.
Almirall, LLC, 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2200051 02/2023